TCT-172 Everolimus-Eluting Bioresorbable Vascular Scaffolds for Percutaneous Treatment of Chronic Total Coronary Occlusions: 1 Year Optical Coherence Tomography findings from the GHOST-CTO Registry

TCT-172 Everolimus-Eluting Bioresorbable Vascular Scaffolds for Percutaneous Treatment of Chronic Total Coronary Occlusions: 1 Year Optical Coherence Tomography findings from the GHOST-CTO Registry

The procedural feasibility and mid-terms outcomes of BVS in CTOs have been already tested, however there is still a paucity of data regarding the vascular response to BVS in CTO setting evaluated by optical coherence tomography (OCT). At OCT analysis there was a trend (p=0.07) towards increased mean...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B74-B74
Hauptverfasser: La Manna, Alessio, Miccichè, Eligio, D'Agosta, Guido, Rodrigues Pereira, Gabriel Tensol, Attizzani, Guilherme F., Capranzano, Piera, Capodanno, Davide, Tamburino, Corrado
Format: Artikel
Sprache:eng
Schlagworte:
Biocompatibility
Biomedical materials
Cardiology
Inhibitor drugs
Optical Coherence Tomography
Percutaneous treatment
Scaffolds
Surgical implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The procedural feasibility and mid-terms outcomes of BVS in CTOs have been already tested, however there is still a paucity of data regarding the vascular response to BVS in CTO setting evaluated by optical coherence tomography (OCT). At OCT analysis there was a trend (p=0.07) towards increased mean scaffold area and significant reductions in mean lumen diameter (3.1±0.36 vs. 2.85±0.47; p=0.0046), mean lumen area (7.8±1.73 vs. 6.76±2; p=0.0082) and minimal lumen area (5.26±1.86 vs. 3.56±1.52; p
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.239